Research ArticleResearch
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)
Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao and Maureen Cruz
PDA Journal of Pharmaceutical Science and Technology September 2022, 76 (5) 369-383; DOI: https://doi.org/10.5731/pdajpst.2021.012693
Melisa J. Masuda-Herrera
1Nonclinical Safety and Pathobiology (NSP), Gilead Sciences, Inc., Foster City, CA, USA;
Joel P. Bercu
1Nonclinical Safety and Pathobiology (NSP), Gilead Sciences, Inc., Foster City, CA, USA;
Thomas H. Broschard
2Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany;
Anders Burild
3Safety Sciences, Imaging and Data Management, Novo Nordisk A/S, Novo Nordisk Park 2760 Måløv, Denmark;
Catrin Hasselgren
4Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080;
Patricia Parris
5Pfizer Worldwide Research and Development, Sandwich, United Kingdom;
Lucie C. Ford
6Department of Veterinary Integrative Biosciences, Interdisciplinary Faculty of Toxicology Program, Texas A&M University, 4466 TAMU, College Station, TX, 77843-4466;
Jessica Graham
4Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080;
Brad Stanard
7Ultragenyx Pharmaceutical Inc., Novato, CA;
Michele Comerford
8Pfizer Global Research & Development, Groton, CT, 06340;
Daniel Lettiere
8Pfizer Global Research & Development, Groton, CT, 06340;
Steffen Erler
9Wella Company, Berliner Allee 65, 64295 Darmstadt, Germany;
Courtney M. Callis
10Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN;
Eric Morinello
4Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080;
Wolfgang Muster
11Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland;
Elizabeth A. Martin
12Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom;
Troy R. Griffin
13Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, 19380; and
Lee Nagao
14Faegre Drinker Biddle & Reath LLP, Washington, DC
Maureen Cruz
14Faegre Drinker Biddle & Reath LLP, Washington, DC
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 76, Issue 5
September/October 2022
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)
Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao, Maureen Cruz
PDA Journal of Pharmaceutical Science and Technology Sep 2022, 76 (5) 369-383; DOI: 10.5731/pdajpst.2021.012693
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)
Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao, Maureen Cruz
PDA Journal of Pharmaceutical Science and Technology Sep 2022, 76 (5) 369-383; DOI: 10.5731/pdajpst.2021.012693
Jump to section
Related Articles
Cited By...
- No citing articles found.
More in this TOC Section
Similar Articles